Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

37 results about "Clostridium botulinum" patented technology

Clostridium botulinum is a Gram-positive, rod-shaped, anaerobic, spore-forming, motile bacterium with the ability to produce the neurotoxin botulinum. The botulinum toxin can cause a severe flaccid paralytic disease in humans and other animals and is the most potent toxin known to mankind, natural or synthetic, with a lethal dose of 1.3–2.1 ng/kg in humans.

Recombinant botulinum toxin and preparation method thereof

ActiveCN119859174ANervous disorderPeptide/protein ingredientsHeavy chainBotulinum toxin type
The invention relates to the technical field of a preparation method of a type A recombinant botulinum toxin, in particular to a type A botulinum toxin obtained by adopting a gene recombination technology, and the amino acid sequence of the type A botulinum toxin is consistent with the sequence of the type A botulinum toxin prepared by extracting and purifying a wild strain Clostridium botulinum. According to the technical scheme, the single-chain protein of the botulinum toxin A sequentially comprises a botulinum toxin A light chain or a modified botulinum toxin A light chain, a connecting region and a botulinum toxin A heavy chain. According to the scheme, the high-quality recombinant botulinum toxin A is obtained after the single-chain protein is subjected to fermentation, crude purification, enzyme digestion and fine purification. According to the technical scheme, the problems of complex process, long period, high safety risk and the like in the existing process for preparing the botulinum toxin A from the wild bacterial strain clostridium botulinum can be solved, and meanwhile, the problem that the amino acid sequence consistent with that of the botulinum toxin A prepared from the wild bacterial strain clostridium botulinum cannot be obtained through the existing gene recombination technology is solved.
Owner:LEPU JIANTANG PHARMACEUTICAL (CHONGQING) CO LTD

Culture medium composition for preparing botulinum toxin

The present invention relates to a culture medium composition for producing botulinum toxin, and more particularly, to a culture medium composition for culturing Clostridium species capable of producing botulinum toxin. The culture medium composition of the present invention comprises casein hydrolysate and at least one plant-derived proteose peptone selected from the group consisting of pea hydrolysate, cottonseed hydrolysate, and wheat gluten hydrolysate. When Clostridium botulinum is cultured using the culture medium according to the present invention containing plant-derived proteose peptone, casein hydrolysate, and minerals, the growth rate of the bacteria in the culture medium is higher than that in each of the currently used culture medium and the culture medium containing only plant-derived proteose peptone. In addition, when the culture medium of the present invention is used, it is possible to produce a high concentration of botulinum toxin by culturing the bacteria in a safe manner.
Owner:DAEWOONG CO LTD

Agents for the treatment of non-replicating bacteria

PCT designated stage expiredWO2025049804A3Peptide/protein ingredientsPeptidesDiseaseBacillus cereus
In one aspect, the invention relates to compounds useful as hybrid antibiotics, acting as both activators of the ClpP protease and inhibitors of RNA polymerase activity. Also disclosed are methods of using the disclosed compounds in the treatment of infectious diseases such as, for example, biofilm-mediated diseases and infectious diseases due to prosthetic joint infections, intracellular bacteria, and Gram-positive bacteria (e.g., Gram-positive bacteria selected from Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Clostridium difficile, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Listeria ivanovii, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus hyicus, Staphylococcus intermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC +1

Clostridium botulinum neurotoxin serotype a compositions and improved filtration processes

PCT designated stage expiredWO2025111258A1Bacterial antigen ingredientsDepsipeptidesVirologyBotulinum toxin type C
Provided herein are compositions comprising Clostridium botulinum neurotoxin serotype A (BoNT / A) with improved stability. Such BoNT / A compositions are produced by a process comprising filtering a solution comprising BoNT / A with a filter that is not gamma-irradiated or a filter that contains no free radicals or a low amount of free radicals. Further provided herein are methods of producing compositions comprising BoNT / A by filtering a solution comprising BoNT / A with a filter that is not gamma-irradiated or a filter that contains no free radicals or a low amount of free radicals.
Owner:ABBVIE INC

Pharmaceutical Preparation for Topical Delivery of Botulinum Toxin

A pharmaceutical composition, method of making and treating, comprising one or more proteins of Clostridium botulinum in a nano-emulsion for topical delivery to treat primarily skin disorders. In an embodiment, the nano-emuslisons are encapsulated microspheres and nanospheres comprising: propylene glycol, phenoxyethanol, sodium hyaluronate, caprylic / capric triglyceride, hydrogenated castor oil, span-80, and saponin, with water. A method of making the nanoemulsions, comprises: (1) preparing a solution A by mixing sodium hyaluronate, propylene glycol, Tween-80 and saponin in water by continuous stirring; (2) preparing a solution B by mixing phenoxy ethanol and carylic acid, or capric triglyceride, together; (3) mixing B into A by continuous stirring for 15 minutes to form solution C; (4) mixing Botulinum toxin and 10 mM Sodium Phosphate buffer to a pH of 7.1, and adding to solution C; and (5) stirring solution C at room temperature for 15-20 minutes.
Owner:INSTITUTE OF ADVANCED SCIENCES

Protein complex including botulinum toxin translocation domain and endolysin and antibacterial composition including same

Provided is a protein complex including a botulinum toxin translocation domain and endolysin. When used, the protein complex including a botulinum translocation domain and endolysin according to the present invention exhibits an antibacterial effect and thus can be used as an antibacterial composition or an antibiotic.
Owner:MVRIX CO LTD

New application of agricultural enzyme and method for controlling soil pathogenic bacteria biological pollution

The application discloses a new use of an agricultural enzyme and a method for controlling and inhibiting soil pathogenic bacteria biological pollution, wherein the agricultural enzyme is used as a soil repair agent to prevent or treat soil pathogenic bacteria biological pollution, and the soil pathogenic bacteria are at least one of Klebsiella pneumoniae, Acidovorax xylosoxidans, Streptomyces orientatis, Vibrio cholerae, Riemerella anatipestifer, Clostridium botulinum, Serratia marcescans, Rhodococcus globerulus and Aeromonas salmonicida. The agricultural enzyme is applied to the pathogenic bacteria biological pollution soil to be treated in different ways. The application directly kills the pathogenic bacteria or regulates the soil microbial community through a quorum sensing gene and a virulence factor gene, so that the abundance of the pathogenic bacteria in the soil community is reduced, and the soil pathogenic bacteria biological pollution is reduced. The application is an economic, green, convenient, efficient agricultural soil environment repair technology.
Owner:ZHEJIANG GONGSHANG UNIVERSITY

Clostridium botulinum neurotoxin serotype a compositions

PendingUS20250032595A1Bacterial antigen ingredientsBacteriaBacilliBotulinum toxin type C
The present disclosure relates to Clostridium botulinum neurotoxin serotype A (BoNT / A) compositions with a plurality of 900 kDa Clostridium botulinum neurotoxin serotype A (BoNT / A) complex species. Provided herein are compositions comprising BoNT / A that have a low level of oxidation at specific methionine positions of 150 kDa BoNT / A. Further provided herein are methods of producing a composition comprising BoNT / A using a low temperature during the process of fermenting Clostridium botulinum bacteria
Owner:ABBVIE INC

Medium composition for botulinum toxin production by culturing of Clostridium botulinum

ActiveUS12398363B2BacteriaDepsipeptidesBotulism toxinYeast cell extract
Disclosed are a medium composition for culturing Clostridium botulinum comprising a potato peptone, a yeast extract and glucose, and a method of preparing a botulinum toxin using the same. The medium excludes animal-derived products and major allergens, and enables the botulinum toxin-producing strain to reach the maximum growth level within a short time, thereby providing effects of shortening the production time and reducing the production cost in the botulinum toxin production process.
Owner:JETEMA CO LTD

Clostridium botulinum neurotoxin serotype a compositions and improved drying processes

PCT designated stage expiredWO2025155814A1Bacterial antigen ingredientsPowder deliveryAlbuminBotulinum toxin type C
Provided herein are solid compositions comprising Clostridium botulinum neurotoxin serotype A (BoNT / A) and human serum albumin (HSA), wherein the solid compositions comprise a low amount of HSA aggregates. Further provided herein are methods of producing solid compositions comprising BoNT / A and HSA by drying a solution comprising BoNT / A in a manner such that the solution does not undergo freezing during drying.
Owner:ABBVIE INC

Agents for the treatment of non-replicating bacteria

PCT designated stage expiredWO2025049804A2PeptidesCyclic peptide ingredientsDiseaseBacillus cereus
In one aspect, the invention relates to compounds useful as hybrid antibiotics, acting as both activators of the ClpP protease and inhibitors of RNA polymerase activity. Also disclosed are methods of using the disclosed compounds in the treatment of infectious diseases such as, for example, biofilm-mediated diseases and infectious diseases due to prosthetic joint infections, intracellular bacteria, and Gram-positive bacteria (e.g., Gram-positive bacteria selected from Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Clostridium difficile, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Listeria ivanovii, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus hyicus, Staphylococcus intermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC +1

Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma

ActiveUS12208073B2Muscular disorderSkeletal disorderPhysiologyOnabotulinum toxin
The present invention provides a composition comprising HMB. Methods of administering HMB to an animal are also described. HMB is administered to enhance recovery from soft tissue trauma, including both acute and non-acute soft tissue trauma. Enhanced recovery includes reduced recovery time and enhanced soft tissue healing. Soft tissue trauma includes administration of a Botulinum toxin, such as Botox. Administration of HMB in association with administration of a Botulinum toxin increases muscle strength and / or function in muscle, including adjacent and / or contralateral muscles and prevents or lessens loss of contractile material.
Owner:METABOLIC TECHNOLOGIES LLC

Clostridium botulinum neurotoxin serotype a compositions

PendingUS20250032596A1Bacterial antigen ingredientsBacteriaBacilliBotulinum toxin type C
The present disclosure relates to Clostridium botulinum neurotoxin serotype A (BoNT / A) compositions with a plurality of 900 kDa Clostridium botulinum neurotoxin serotype A (BoNT / A) complex species. Provided herein are compositions comprising BoNT / A that have a low level of oxidation at specific methionine positions of 150 kDa BoNT / A. Further provided herein are methods of producing a composition comprising BoNT / A using a low temperature during the process of fermenting Clostridium botulinum bacteria
Owner:ABBVIE INC

Clostridium botulinum Serotype A Neurotoxin (BoNT / A) Sequence Variants

ActiveGB2627864BClostridialesBotulinum toxin type C
A composition comprising a Clostridium botulinum neurotoxin serotype A (BoNT / A) complex comprising a plurality of variant species, wherein the variant species comprises BoNT / A with a C-terminal trunca
Owner:ABBVIE INC

Medium composition for the preparation of botulinum toxin

The present invention relates to a culture medium composition for producing botulinum toxin, and more particularly to a culture medium composition for culturing Clostridium sp. strains capable of producing botulinum toxin. When a Clostridium botulinum strain is cultured using a culture medium comprising vegetable peptone, glucose, and yeast extract without animal-derived components, the growth rate of the strain is increased compared to existing culture media, and the strain can be safely cultured since animal-derived components are not included, thereby increasing the yield of botulinum toxin.
Owner:DAEWOONG CO LTD

Method of preparing toxin

Disclosed are a medium composition for culturing Clostridium botulinum comprising a potato peptone, a yeast extract and glucose, and a method of preparing a botulinum toxin using the same. The medium excludes animal-derived products and major allergens, and enables the botulinum toxin-producing strain to reach the maximum growth level within a short time, thereby providing effects of shortening the production time and reducing the production cost in the botulinum toxin production process.
Owner:JETEMA CO LTD

Medium composition for preparing botulinum toxin

PCT designated stage expiredWO2025100868A1BacteriaPeptidasesBiotechnologyYeast cell extract
The present invention relates to a medium composition for producing botulinum toxin and, more specifically, to a medium composition for culturing Clostridium sp. strains capable of producing botulinum toxin. When a medium containing vegetable peptone, glucose, and yeast extracts and not containing animal-derived components according to the present invention is used for culturing Clostridium botulinum strains, the strain growth rate is increased compared to the existing mediums, and the strains can be safely cultured due to not containing animal-derived components, thereby increasing the productivity of botulinum toxin.
Owner:DAEWOONG CO LTD

Method for preparing botulinum toxin

The present invention relates to a botulinum toxin preparation method capable of obtaining botulinum toxin in a high yield through a simplified process that does not include animal-derived ingredients. The botulinum toxin preparation method according to the present invention does not use any animal ingredients in the overall process, including the culturing of a Clostridium botulinum strain, thereby providing excellent safety, omits a separate nucleic acid removal step using an additive treatment when compared with a conventional isolation process, and performs processing using only ion exchange chromatography, and it was confirmed that the botulinum toxin can be isolated at a remarkably improved yield through a simplified process by using the same buffer and only adjusting the concentration and pH of the buffer, and thus the present invention is a very economical and efficient isolation method so that the botulinum toxin isolated thereby is expected to be effectively used in beauty and medicine fields.
Owner:PROTOX INC

Bacterial prevention in low acid beverages

Shelf-stable packaged low acid-beverages and methods for the same are disclosed. The shelf-stable packaged low acid beverage may include a container and a liquid low acid beverage disposed and sealed in the container. The liquid low acid beverage may include oxygen dissolved therein in an amount sufficient to prevent growth of bacteria, such as Clostridium botulinum or other bacteria such as Psychotrophs or lactic bacteria. The method may include dissolving the liquid low acid beverage into the container, dissolving oxygen and / or nitrogen into the low liquid beverage disposed in the container, and sealing the container. The container and the liquid low acid beverage may define a headspace disposed in the container. The oxygen may be present in the headspace in an amount greater than 0%, or greater than or equal to about 12%, based on the volume of the headspace.
Owner:KERFLUMMOX HOLDINGS LLC

Clostridium botulinum targeting long-acting slow-release antibacterial preparation as well as preparation method and application thereof

The invention relates to the technical field of food microorganisms, in particular to a long-acting slow-release antibacterial preparation targeting clostridium botulinum spores as well as a preparation method and application of the long-acting slow-release antibacterial preparation. The long-acting slow-release bacteriostatic preparation comprises a wall material and a core material, the core material comprises a lactic acid bacteria metabolite and a spore coating penetrant; the wall material is prepared from konjac glucomannan, tannic acid, polylysine salt and hyaluronic acid. By preparing a core material compound and embedding the core material compound in a wall material microcapsule, a three-layer action system of spore coating damage, skin layer degradation and core metabolism inhibition is constructed. The preparation can significantly improve the targeting and stability of antibacterial components, realizes complete substitution of nitrite in meat products, has the characteristics of safety, high efficiency and long acting, and conforms to the national food safety and health industrial policy.
Owner:QILU UNIVERSITY OF TECHNOLOGY (SHANDONG ACADEMY OF SCIENCES)

Clostridium botulinum serotype A neurotoxin (BoNT / A) sequence variants

ActiveUS12502420B2BacteriaPeptide/protein ingredientsClostridialesBotulinum toxin type C
Provided herein are compositions comprising a Clostridium botulinum neurotoxin serotype A (BoNT / A) complex comprising a 150 kDa BoNT / A. Said 150 kDa BoNT / A is in the form of a plurality of sequence variant species, wherein the plurality of sequence variant species comprises a 150 kDa BoNT / A sequence variant species with a C-terminal truncated light chain.
Owner:ABBVIE INC

Refrigerated processed foods that can be stored for a long period of time and a method for storing the same

A shelf-stable refrigerated processed food (REPFED) having a pH value of at least 4.6, wherein the REPFED at a temperature between 0° C. and 10° C. is free of vegetative Listeria monocytogenes and / or Streptococcus faecalis and / or Clostridium botulinum and Bacillus cereus, and wherein these bacteria are killed and the spores of these bacteria are at least fatally damaged and are no longer capable of developing and growing into the bacteria. Also disclosed is a method (1) for preserving said REPFED stored in a refrigerator.
Owner:COROOS BEHEER BV

Recombinant botulinum toxin and preparation method therefor

PCT designated stageWO2026148729A1Enzyme digestionHeavy chain
The present invention relates to the technical field of a method for preparing a recombinant botulinum toxin type A, and particularly relates to a botulinum toxin type A obtained by means of gene recombination technology, the amino acid sequence of which is identical to the sequence of botulinum toxin type A prepared by means of extraction and purification from a wild Clostridium botulinum strain. Provided is a single-chain protein of botulinum toxin type A, sequentially comprising: a light chain of botulinum toxin type A or a modified light chain of botulinum toxin type A, a linking region, and a heavy chain of botulinum toxin type A. The single-chain protein is subjected to fermentation, crude purification, enzyme digestion, and fine purification to obtain high-quality recombinant botulinum toxin type A. The present invention can solve the existing problems of complex process, long period, high safety risk and the like in the preparation of botulinum toxin type A by using wild Clostridium botulinum strains, and also solve the existing problem that the amino acid sequence of botulinum toxin type A prepared by means of gene recombination technology cannot be identical to that of botulinum toxin type A prepared by wild Clostridium botulinum strains.
Owner:LEPU JIANTANG PHARMACEUTICAL (CHONGQING) CO LTD

Filtering and sterilizing device for botulinum toxin

The utility model discloses a filtering and sterilizing device for botulinum toxin, which relates to the technical field of botulinum toxin sterilizing and filtering and comprises a storage bottle, a liquid pump, a pressure valve, a membrane filter, a breaker, two liquid stopping clamps, three hoses and a collecting bottle. The three hoses are respectively a hose I, a hose II and a hose III, the hose I is connected between the output end of the storage bottle and the input end of the liquid pump, the hose II is connected between the output end of the liquid pump and the input end of the membrane filter, and the hose III is connected between the output end of the membrane filter and the input end of the collection bottle. In the process of filtering the botulinum toxin solution, the botulinum toxin solution can be in a closed environment in the whole process, and the risk that clostridium botulinum aerosol in the air pollutes the filtered solution in the thallus separation process can be effectively avoided, so that the condition that viable bacteria in the process of the section enter the process of the next section is effectively prevented, and the quality of the botulinum toxin solution is improved. The biological safety risk is reduced.
Owner:SHANGHAI OUXUEYUMEI MEDICAL BEAUTY CLINIC CO LTD

Clostridium botulinum serotype a neurotoxin (bont / a) sequence variants

The present disclosure relates to methods for preparing Clostridium botulinum working cell bank. Further provided herein are methods of producing a composition comprising a 900 kDa BoNT / A complex, said method comprising an acid precipitation step.
Owner:ABBVIE INC